Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Why Big Tech Sees Value in Healthcare Data

The COVID-19 pandemic hit just as many countries were finding their long-term stride around value-based care, one of the leading strategies for reimagining global health systems. Pushing up on ten years after the publication of the study, “The Strategy That Will Fix Healthcare,” we have a better picture of what is and isn’t working…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The COVID-19 pandemic hit just as many countries were finding their long-term stride around value-based care, one of the leading strategies for reimagining global health systems. Pushing up on ten years after the publication of the study, “The Strategy That Will Fix Healthcare,” we have a better picture of what is and isn’t working in a value-based strategy as businesses turn their investment eyes to the healthcare industry. With high-profile investments from Big Tech in care data incubators and partnerships, how will value-based care intersect with their desire for capturing new marketshare?

Sitting down to give insights with Voice of B2B Daniel Litwin is Etan Walls, Principal, Strong Walls Consulting. Walls brings senior-level corporate experience to operational consulting for things like strategic planning, organizational change management, and more. He previously served as COO of the Allied Physicians Group, a New York partnership of private medical practices.

“From my perspective, I’d probably rate how we’re doing a C-.” -Etan Walls

They discuss strategic business partnerships in healthcare that are focusing on data as their solution, why big tech companies are being drawn to this space for business opportunities, and better understanding how data should support transitions to reimagined care in the U.S., specifically value-based care. But, even as the country shifts toward more equitable healthcare, it still isn’t doing that great.

“We need to understand where we are with value-based care and rate the system as a whole,” Walls said. “From my perspective, I’d probably rate how we’re doing a C-. We are affecting change in important areas, but we’re really basing a system that is built around incentivizing/penalizing insurance companies, incentivizing/penalizing individual providers of care, their systems of care, and we really haven’t gone to the third leg of the stool, which is the patient.”

The real change will occur when these three areas can synchronize, according to Walls. Large tech/healthcare partnerships are happening to fill the gap, such as AWS launching a four-week healthcare accelerator for startups in the public sector. Google Cloud & HCA Healthcare announced a partnership to elevate clinical decision support technologies. But, these might not be enough, according to a study by NEJM Catalyst, that shows that value-based healthcare implementation is weak across the board.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512